|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.33 SEK | -.--% |
|
-0.85% | -24.84% |
| May. 22 | Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
Enorama Pharma AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 0.172 million compared to SEK 0.032 million a year ago. Negative revenue was SEK 0.384 million compared to SEK 0.282 million a year ago.
Net loss was SEK 13.75 million compared to SEK 13.1 million a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -24.84% | 9M | |
| +15.91% | 42.02B | |
| +22.40% | 21.66B | |
| +18.48% | 15.09B | |
| +16.12% | 14.21B | |
| +45.12% | 12.37B | |
| -0.05% | 6.79B | |
| -9.58% | 6.59B | |
| -8.87% | 5.73B | |
| +14.18% | 5.56B |
ENORAMA PHARMA AB 
